C. Boyce

发表

Recent advances in the development of histamine H3 antagonists

M. Berlin, C. Boyce, 2007, Expert opinion on therapeutic patents.

CC-1065 and the Duocarmycins: Synthetic Studies.

D. Boger, C. Boyce, R. Garbaccio, 1997, Chemical reviews.

Pharmacological Evaluation of Selective α2c-Adrenergic Agonists in Experimental Animal Models of Nasal Congestion

M. Koss, J. Hey, J. Hunter, 2014, The Journal of Pharmacology and Experimental Therapeutics.

Reduction of hERG inhibitory activity in the 4-piperidinyl urea series of H3 antagonists.

Walter A. Korfmacher, S. Sorota, R. Aslanian, 2010, Bioorganic & medicinal chemistry letters.

Pharmacological characterization of the late phase reduction in lung functions and correlations with microvascular leakage and lung edema in allergen-challenged Brown Norway rats.

P. Mauser, C. Correll, R. Chapman, 2013, Pulmonary pharmacology & therapeutics.

Pharmacological Characterization of a Novel α2C-Adrenoceptor Agonist N-[3,4-dihydro-4-(1H-imidazol-4-ylmethyl)-2H-1, 4-benzoxazin-6-yl]-N-ethyl-N′-methylurea (Compound A)

Walter A. Korfmacher, Y. Wan, S. Umland, 2011, Journal of Pharmacology and Experimental Therapeutics.

Pharmacological Characterization of a Novel (cid:1) 2C -Adrenoceptor Agonist N- [3,4-dihydro-4-(1 H -imidazol-4-ylmethyl)-2 H -1, 4-benzoxazin-6-yl]- N -ethyl- N (cid:1) -methylurea (Compound A)

Walter A. Korfmacher, Y. Wan, S. Umland, 2011 .

Role of α2-adrenoceptors in Electrical Field Stimulation–induced Contraction of Pig Nasal Mucosa and Pharmacologic Characterization of a Novel α2C-adrenoceptor Agonist

M. Corboz, J. Hunter, R. Chapman, 2013, American journal of rhinology & allergy.

Alpha-2c-Adrenergic Receptors Contribute to Basal Nasal Patency in the Anesthetized Cat

M. Corboz, R. Mcleod, C. Boyce, 2010, Pharmacology.

Synthesis, Chemical Properties, and Preliminary Evaluation of Substituted CBI Analogs of CC-1065 and the Duocarmycins Incorporating the 7-Cyano-1,2,9,9a-tetrahydrocyclopropa[c]benz[e]indol-4-one Alkylation Subunit: Hammett Quantitation of the Magnitude of Electronic Effects on Functional Reactivity

D. Boger, C. Boyce, H. Cai, 1996 .

Resolution of a CPzI precursor, synthesis and biological evaluation of (+) and (-)-N-Boc-CPzI: a further validation of the relationship between chemical solvolytic stability and cytotoxicity.

D. Boger, G. Spalluto, B. Cacciari, 1999, Bioorganic & medicinal chemistry letters.

pH Dependence of the rate of DNA alkylation for (+)-duocarmycin SA and (+)-CCBI-TMI

D. Boger, Douglas S. Johnson, C. Boyce, 1997 .

Total Syntheses of Ningalin A, Lamellarin O, Lukianol A, and Permethyl Storniamide A Utilizing Heterocyclic Azadiene Diels−Alder Reactions

D. Boger, C. Sehon, C. Boyce, 1999 .

Total synthesis of ningalin B utilizing a heterocyclic azadiene Diels-Alder reaction and discovery of a new class of potent multidrug resistant (MDR) reversal agents.

D. Boger, M. Hedrick, Q. Jin, 2000, The Journal of organic chemistry.

Total Syntheses of Ningalin A (V), Lamellarin O (VI), Lukianol A (VII), and Permethyl Storniamide A (VIII) Utilizing Heterocyclic Azadiene Diels—Alder Reactions.

D. Boger, C. Sehon, C. Boyce, 1999 .

Histamine H3 receptor as a drug discovery target.

Michael Berlin, M. L. Ruiz, Christopher W Boyce, 2011, Journal of medicinal chemistry.

Synthesis of CC-1065 and duocarmycin analogs via intramolecular aryl radical cyclization of a tethered vinyl chloride

D. Boger, M. Searcey, C. Boyce, 1998 .

CBI Prodrug Analogs of CC-1065 and the Duocarmycins

D. Boger, M. Searcey, C. Boyce, 1999 .

Asymmetric Synthesis of the CBI Alkylation Subunit of the CC-1065 and Duocarmycin Analogs

D. Boger, J. A. Mckie, C. Boyce, 1997 .

Synthesis and SAR studies of benzimidazolone derivatives as histamine H3-receptor antagonists.

Walter A. Korfmacher, J. Hey, R. Aslanian, 2013, Bioorganic & Medicinal Chemistry Letters.

Evaluating Spray Drying and Co-precipitation as Manufacturing Processes for Amorphous Solid Dispersions of a Low Tg API.

Marina A. Solomos, Luke Schenck, M. Lamm, 2023, Journal of Pharmacy and Science.

The Invention of WM382, a Highly Potent PMIX/X Dual Inhibitor toward the Treatment of Malaria.

Manuel de Lera Ruiz, A. Cowman, Zhuyan Guo, 2022, ACS medicinal chemistry letters.

Histamine H3 receptor as a drug discovery target.

M. L. Ruiz, M. Berlin, C. Boyce, 2011, Journal of medicinal chemistry.